Reduced JAK Inhibitor Dosing May Not Compromise RA Outcomes
A study found that patients with rheumatoid arthritis who started on reduced doses of JAK inhibitors maintained similar treatment persistence and disease control as those on standard doses over 24 months. The research included 1,135 patients with preserved kidney function and showed no significant differences in drug retention between the two dosing groups. However, patients with more poor prognostic factors had a lower risk of discontinuation when on standard doses compared to reduced doses.
- ▪The study involved 1,135 patients with rheumatoid arthritis from multiple Japanese centers.
- ▪Patients were categorized based on whether they received standard or reduced doses of JAK inhibitors.
- ▪24-month drug retention rates were comparable between the reduced-dose and standard-dose groups for patients with preserved renal function.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/reduced-jak-inhibitor-dosing-may-not-compromise-ra-outcomes-2026a1000gyv?src=rss |
| Publication time | Mon, 25 May 2026 03:17:09 EDT |
| Retrieval time | 2026-05-25T07:37:36.533Z |
| Last seen | 2026-05-25T07:37:36.533Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | YVEPKoR_HVHR |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Patients with rheumatoid arthritis (RA) and preserved kidney function who started reduced doses of JAK inhibitors had treatment persistence and disease control that were similar to those in patients who started standard doses over 24 months of follow‑up.METHODOLOGY:Researchers conducted an observational cohort study to compare 24‑month treatment persistence between standard‑dose and reduced‑dose JAK inhibitors in patients with RA, with a primary focus on those with preserved renal function.They included 1135 patients from a registry (ANSWER) who started treatment with JAK inhibitors at multiple Japanese centers between March 2013 and October 2025.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
